J Rheum Dis.  2014 Oct;21(5):274-277. 10.4078/jrd.2014.21.5.274.

A Case of Infliximab-induced Psoriasis in Treatment of Ankylosing Spondylitis

• Kim MJ
• Lee JH
• Im HJ
• Yeo HJ
• Lee HJ
• Byun KS

• KMID: 2222954
• DOI: http://doi.org/10.4078/jrd.2014.21.5.274

Abstract

Infliximab, which is indicated for refractory rheumatoid arthritis (RA), ankylosing spondylitis (AS) and Crohn's disease, has cutaneous adverse events including skin rash, urticaria, pruritus, and lupus-like eruption. Psoriasis induced by infliximab is very rare. In Korea, it is infrequently reported in Crohn's disease or RA and never reported in AS. We encountered a case of psoriasis induced by infliximab treatment for AS, and report here on this case along with a review of the relevant literature.

Keyword

Infliximab; Psoriasis; Ankylosing spondylitis

MeSH Terms

Arthritis, Rheumatoid
Crohn Disease
Exanthema
Korea
Pruritus
Psoriasis*
Spondylitis, Ankylosing*
Urticaria
Infliximab

Figure

• 

  Figure 1. (A) Erythematous scaly plaques on extensor surfaces of lower extremities (B) pustules with reddened skin of palm.

• 

  Figure 2. Anteroposterior radiograph of the pelvis showing periarticular erosions and sclerosis of both sacroiliac joints.

• 

  Figure 3. Microscopic finding of the skin lesion. Hyperkeratosis, dermal papillar elongation, perivascular lymphocytic infiltration were seen (H&E stain, ×100).

Reference

1. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005; 7:R666–76.

2. Famenini S, Wu JJ. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases. J Drugs Dermatol. 2013; 12:939–43.

3. Kim JY, Choi M, Cho KH. A case of pustular psoriasis developed during infliximab treatment for crohn's disease. Korean J Dermatol. 2012; 50:810–3.

4. Jwa YJ, Kim NH, Park HJ, Park JS, Bae WK, Kim KA, et al. A case of psoriasis induced by infliximab treatment for Crohn's disease. Korean J Gastroenterol. 2010; 56:324–8.

5. Park BC, Lim HJ, Kim BS, Lee WJ, Kim do W, Lee SJ. Repeated Paradoxical Aggravation of Preexisting Psoriasis during Infliximab Treatment for Crohn's Disease. Ann Dermatol. 2009; 21:60–2.

6. Choi YJ, Kim DS, Park JM, Oh SH, Park YK, Lee JH. A case of psoriasiform eruption triggered by tumor necrosis factor-alpha antagonist therapy. Korean J Dermatol. 2008; 46:721–3.

7. Kim SY, Kim GM, Kim SY. Case of recurrent generalized pustular psoriasis treated with a combination of infliximab with methotrexate and retinoid. Korean J Dermatol. 2006; 44:67–70.

8. Oh JM, Koh EM, Kim H, Lee J, Ahn JK, Cha HS, et al. Exacerbation of psoriatic skin lesion followed by tnfalpha antagonist treatment. J Korean Rheum Assoc. 2010; 17:200–4.

9. Park JJ, Lee SC. A Case of Tumor Necrosis Factor-alpha Inhibitors-induced Pustular Psoriasis. Ann Dermatol. 2010; 22:212–5.

10. Hahn HJ, Jung JW, Park HJ, Lee YW, Choe YB, Ahn KJ. A case of psoriasiform dermatitis following adalimumab injection for treatment of ankylosing spondylitis. Korean J Dermatol. 2013; 51:743–5.

11. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009; 361:496–509.

12. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009; 58:501–8.

13. Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol. 2012; 30:700–6.

14. Gilliet M, Conrad C, Geiges M, Cozzio A, Thürlimann W, Burg G, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004; 140:1490–5.

15. Aeberli D, Seitz M, Jüni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford). 2005; 44:172–5.